|
07 Nov 2018 |
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
|
|
07 Nov 2018 |
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
|
|
07 Nov 2018 |
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
|
|
07 Nov 2018 |
Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
|
|
03 Nov 2018 |
U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)
|
|
29 Oct 2018 |
Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic
|
|
28 Oct 2018 |
Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin
|
|
25 Oct 2018 |
Scarless Laboratories Receives FDA Clearance to Initiate Phase I/IIa Trial of SLI-F06 Peptide for Scar Reduction
|
|
24 Oct 2018 |
Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
|
|
23 Oct 2018 |
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
|
|
22 Oct 2018 |
amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress
|
|
21 Oct 2018 |
Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting
|
|
19 Oct 2018 |
Kuros Biosciences advances its Fibrin-PTH (KUR-113) spinal fusion product candidate program
|
|
19 Oct 2018 |
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
|
|
19 Oct 2018 |
Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease
|
|
19 Oct 2018 |
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
|
|
16 Oct 2018 |
Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206
|
|
10 Oct 2018 |
Fresenius Kabi’s pegfilgrastim biosimilar candidate MSB11455 met its primary endpoints in the two pivotal clinical studies
|
|
06 Oct 2018 |
FDA Approves Revcovi™, a New Enzyme Replacement Therapy Developed by Leadiant Biosciences, for the Treatment of ADA-SCID in Pediatric and Adult Patients
|
|
04 Oct 2018 |
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
|
|
02 Oct 2018 |
Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
|
|
02 Oct 2018 |
Inotrem Announces Positive Results From the Phase IIa Study of Its Lead Compound, Nangibotide (LR12), in the Treatment of Septic Shock
|
|
02 Oct 2018 |
Torque Announces the Presentation of Preclinical Data for Deep IL-15 Primed T Cells Demonstrating Superior T Cell Expansion, Persistence, and Safety Compared with Systemically Administered IL-15
|
|
02 Oct 2018 |
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
|
|
30 Sep 2018 |
New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
|
